Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis (PRIME)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01324232 |
|
Recruitment Status :
Completed
First Posted : March 28, 2011
Last Update Posted : January 16, 2018
|
Sponsor:
Avanir Pharmaceuticals
Information provided by (Responsible Party):
Avanir Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | September 2013 |
| Actual Study Completion Date : | September 2013 |
| Certification/Extension First Submitted : | January 8, 2018 |